CODX vs EXPE · rev $3.9M vs P/E 20, rev $13.69B
Co-Diagnostics, Inc. Common Stock (CODX) versus Expedia Group Inc. (EXPE) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported EXPE revenue for 2024-12-31 was $13.69B. Net income was $1.22B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
CODX currently screens at market cap $31.4M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Not investment advice. Open the CODX and EXPE stock pages for the full models.
Not investment advice.